Document is current

Any future updates will be listed below

Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma

Crossref DOI link: https://doi.org/10.1007/s10637-014-0186-2

Published Online: 2014-11-13

Published Print: 2015-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark